Nykredit A S Takes $8.78 Million Position in West Pharmaceutical Services, Inc. $WST

Key Points

• Nykredit A/S acquired 24,456 shares of West Pharmaceutical Services during the second quarter, valued at approximately $8.78 million. Institutional investors collectively own 93.9% of the company.
• Analysts maintain a positive outlook, with 11 Buy ratings and three Holds, producing a “Moderate Buy” consensus and an average price target of $379.08.
• West Pharmaceutical Services exceeded quarterly expectations, reporting $2.37 in EPS and $872.3 million in revenue, while revenue increased 13.8% year over year. The company also declared a quarterly dividend of $0.22 per share.

Nykredit A S bought a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 24,456 shares of the medical instruments supplier's stock, valued at approximately $8,780,000.

A number of other large investors also recently modified their holdings of WST. Cornerstone Planning Group LLC raised its holdings in West Pharmaceutical Services by 90.9% during the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier's stock worth $26,000 after buying an additional 50 shares during the last quarter. Bayban bought a new position in shares of West Pharmaceutical Services in the fourth quarter valued at $27,000. Avalon Trust Co acquired a new position in shares of West Pharmaceutical Services during the second quarter valued at about $28,000. Addison Advisors LLC acquired a new position in shares of West Pharmaceutical Services during the second quarter valued at about $28,000. Finally, Raiffeisen Bank International AG increased its position in shares of West Pharmaceutical Services by 95.6% during the second quarter. Raiffeisen Bank International AG now owns 133 shares of the medical instruments supplier's stock worth $47,000 after acquiring an additional 65 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on WST. UBS Group upped their target price on shares of West Pharmaceutical Services from $340.00 to $415.00 and gave the stock a "buy" rating in a report on Wednesday, September 9th. Morgan Stanley lifted their price target on West Pharmaceutical Services from $325.00 to $365.00 and gave the company an "equal weight" rating in a research note on Thursday, July 9th. TD Cowen reissued a "buy" rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. Zacks Research downgraded West Pharmaceutical Services from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 12th. Finally, Citigroup raised their target price on West Pharmaceutical Services from $400.00 to $412.00 and gave the company a "buy" rating in a report on Monday, August 3rd. Eleven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, West Pharmaceutical Services currently has an average rating of "Moderate Buy" and an average price target of $379.08.

West Pharmaceutical Services Trading Down 0.1%

NYSE:WST opened at $361.82 on Monday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. The firm has a market cap of $25.47 billion, a price-to-earnings ratio of 46.33, a price-to-earnings-growth ratio of 2.53 and a beta of 1.14. West Pharmaceutical Services, Inc. has a 52 week low of $223.83 and a 52 week high of $386.00. The firm has a 50-day moving average price of $349.08 and a two-hundred day moving average price of $314.71.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $2.08 by $0.29. The firm had revenue of $872.30 million for the quarter, compared to analysts' expectations of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The company's quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, equities analysts expect that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were given a $0.22 dividend. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 annualized dividend and a yield of 0.2%. West Pharmaceutical Services's payout ratio is currently 11.27%.

Insiders Place Their Bets

In other West Pharmaceutical Services news, VP Annette Favorite sold 8,135 shares of the company's stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $340.81, for a total value of $2,772,489.35. Following the completion of the transaction, the vice president owned 16,845 shares in the company, valued at $5,740,944.45. This represents a 32.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 15,659 shares of company stock valued at $5,443,749 over the last 90 days. 0.60% of the stock is currently owned by insiders.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc NYSE: WST develops and manufactures components and systems used to package, contain and deliver injectable medicines and other healthcare products. Its customers include pharmaceutical, biotechnology and medical device companies, which use West products in drug administration and medical applications.

The company's offerings include elastomer components such as stoppers, plungers and seals; syringe and cartridge components; vial and container closure systems; and specialized delivery systems for injectable and other complex medicines.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.